<u>Ward Form</u> (Mandatory : Fill in one form for each ward included in the PPS) Include only <u>in</u>patients "admitted before and present at 08:00 hours" on the day of the PPS!

| Date of survey (dd/mm/year) | / | Perso | n completing form (Audito | or code) : | | | | |
|--|--|----------------------------------|--|-------------------------------------|---|--|--|--|
| Hospital name: | | | War | d Name : | | | | |
| | Adı | ult wards | | | Paediatric wards | | | |
| Ward Type: | ☐ AMW (General or mixed Adult Medical Ward) | ☐ ASW (General or m | ☐ ASW (General or mixed Adult Surgical Ward) | | | ☐ PMW (Paediatric Medical Ward) | | |
| Tick the most appropriate type | ☐ HO-AMW (Haematology-Oncology) | ☐ DIG-ASW (Digestive | e tract surgery) | ☐ HO-PMW (Haematology-Oncole | | | | |
| of department/ward | ☐ T-AMW (Transplant (BMT/solid)) | ☐ ORT-ASW (Orthopa | edics-Trauma surg.) | | ☐ T-PMW (Transplant (BMT/Solid)) | | | |
| от вори визия, так | ☐ P-AMW (Pneumology) | ☐ URO-ASW (Urologic | cal surg.) | | □ PSW (Paediatric Surgical Ward) | | | |
| | ☐ CAR-AMW (Cardiology) | ☐ CV-ASW (Cardio-va | scular surg.) | | ☐ PICU (Paedia | atric Intensive Care Unit) | | |
| | □ NEU-AMW (Neurology) | □ NEU-ASW (Neurosu | ırgery) | | □ ID-PMW (Inf | ectious Disease PMW) | | |
| | ☐ REN-AMW (Nephrology) | ☐ ONCO-ASW (Oncole | ogy-cancer surg.) | | | | | |
| | ☐ ID-AMW (Infectious Disease) | ☐ PLAS-ASW (Plastic, | reconstructive surg.) | | Neonatal ward | ds: | | |
| | ☐ DB-AMW (Dermatology-burn wards) | ☐ ENT-ASW (Ear-nose | e-throat surg.) | | □ NMW (Neon | atal Medical Ward) | | |
| | ☐ PSY-AMW (Psychiatry) | | | | ☐ NICU (Neona | atal Intensive Care Unit) | | |
| | ☐ REH-AMW (Rehabilitation) | ☐ AICU (General or m | ixed Adult Intensive Care | Unit) | | | | |
| | ☐ GER-AMW (Geriatrics) | □ MED-AICU (Medical AICU) | | | | | | |
| | ☐ LTC-AMW (Long-Term care) | LTC-AMW (Long-Term care) | | | | | | |
| | ☐ OBG-AMW (gynaecology-obstetrics) | ☐ CAR-AICU (Cardiac | AICU) | | | | | |
| | ☐ IS-AMW (Isolation ward, e.g. COVID patients) | ☐ AHDU (High Depend | dency Unit) | | | | | |
| Mixed Ward | ☐ Yes ☐ No | | | | | | | |
| Activity: Tick as appropriate. In ca | ase of mixed wards, tick all encountered activities/spec | cialities | ☐ Medicine | | ☐ Surgery ☐ Intensiv | | | |
| Total number of admitted inpation | ents (=all patients whether they receive an antimicrob | ial or not !) on the | | | | | | |
| ward present at 8.00 am on day o | of PPS. For mixed departments, fill the total number of | patients | | | | | | |
| corresponding to each of the enco | | | | | | | | |
| | d present at 8:00 am on day of PPS split up by activity. | | | | | | | |
| departments fill in the total numb | per of beds corresponding to each of the encountered | activities. | | | | | | |
| The | e next section is to be filled in 'only' if you are pa | rticipating in the Hea | althcare-Associated Infe | ctions (H | AI) module | | | |
| Total number of | Indwelling | Urinary Catheter (UC) | | | | | | |
| "admitted" inpatients | At least one peripheral vascular / intrav | enous catheter (PVC) | | | | | | |
| with one of the following | Central vascular catheter, no implanta | | | | | | | |
| "inserted" invasive devices | Non-invasive pos. & neg. mechanical ventilation (C | . , , , | | | | | | |
| at 8:00 am on day of PPS | Invasive respiratory endotra | | | | | | | |
| | | · · · | | | | | | |
| Inserted tubes and drains (T/D) ² | | | | | | | | |

² Inserted tubes and drains: include patients with nephrostomy tubes, intra-abdominal tubes and drains, cerebrospinal fluid shunts etc.



¹ Include tracheostomy

GLOBAL-PPS PATIENT Form (Mandatory: Fill in one form per patient with an ongoing antimicrobial at 8am on the day of the PPS)

Patient Age 4

| Ward Name/code Activity ¹ (M, S, IC) | | | | | | | ratient Age | | | rectiate only (optional) | | | |
|---|-------------------------|-------------------------|---------------------------------|------------------------|-----------------------------|-------------------|-------------------------|---|-----------------------------|-----------------------------|-----------------------|----------------|--|
| | | Patient | Patient Identifier ² | | Survey Number ³ | | Months 1-23 month | Days <1 month | Current Weight* In kg | Gestatio- nal age* | Birth weight* (kg) | Sex M, F, U | |
| | | | | | | | | | | | | | |
| Treatment based on bid | omarker data | or WBC | 0 Yes - 0 | No | | Culture(s) sent t | to the lab to do | cument infec | tion* (Tick if | f yes) | | | |
| _ | Тур | | | Most relevar | nt value close to | Blood | Cerek | prospinal flui | d | BAL (pro | tected resp. spe | ecimen) | |
| If yes, which: CRP, PCT, other | sar | logical fluid nple | 5 | start antimic Value | robial Unit ⁶ | ☐ Urine | ☐ Woul | ☐ Wound (surgery/biopsy) ☐ Other type of specimen | | ☐ Sputum/bronchial aspirate | | | |
| or WBC ⁵ | (Blo | ood/urine/ ier) | | | | ☐ Stool | Othe | | | | | | |
| Antimicrobial Name ⁷ | | | 1. | | 2. | | 3. | | 4. | | 5. | | |
| Start date of the antir | nicrobial* (<i>dd,</i> | /mm/yyyy) | | | | | | | | | | | |
| Single Unit Dose 8 | Unit (g, mg, | IU, MU) ⁹ | | | | | | | | | | | |
| Doses/ day 10 | Route (P, O, | R, I, IM) ¹¹ | | | | | | | | | | | |
| Diagnosis 12 (see appe | ndix II) | | | | | | | | | | | | |
| Type of indication ¹³ (s | see appendix II | I) | | | | | | | | | | | |
| Reason in Notes (Yes | • | | | | | | | | | | | | |
| Guideline Compliance | (Y, N, NA, NI) | 15 | | | | | | | | | | | |
| Is a stop/review date | | | | | | | | | | | | | |
| N missed doses*16 | Reason* (S | ,P,O,M,U) ¹⁷ | | | | | | | | | | | |
| Treatment (E: Empirio | cal: T: Targeted | I) ¹⁸ | | | | | | | | | | | |
| The following resist | | • | in only if the | treatment o | choice is based | on microbiolog | gy data (Treat | ment=T) ava | ailable on tl | he day of the | PPS | | |
| Maximum 3 microorg | anisms (MO) t | o report | МО | R type | | R type** | МО | R type** | МО | R type** | | R type** | |
| Insert codes (see App | | • |) 1 | | | | | | | | | | |
| most codes (see App | citaix it, page | MC MC | | | | | 1 | | | | | | |
| | | NAC | | | | | | | | | + + | | |

<u>Resistance type</u>**- choose between: MRSA¹⁹; MRCoNS²⁰; PNSP²¹; MLS²²; VRE²³; ESBL (ESBL-producing Enterobacterales²⁴); 3GCREB (3rd generation cephalosporin resistant Enterobacterales); CRE (Carbapenem-resistant Enterobacterales²⁵); ESBL-NF (ESBL-producing non fermenter Gram-negative bacilli²⁶); CR-NF (Carbapenem-resistant non fermenter Gram-negative bacilli²⁷); other MDRO²⁸; Azoles²⁹. Encode Microorganism also if resistance type is unknown.

Note: * Current weight, Gestational age (in number of weeks), Birth weight, Start date of the antimicrobial and Cultures sent to the lab, missed doses are optional variables.



Neonate only (optional)

- Activity: M=medicine (including Psychiatric cases, etc.), S=surgery (including orthopaedics, obstetrics and gynaecology, etc.), IC=intensive care
- ² Patient Identifier: A unique patient identifier that allows linkage to patient records at local level for more detailed audit. This unique identifier will not be included in the online database.
- ³ <u>Survey Number</u>: A unique non-identifiable number given by WebPPS for each patient entered in the database. Leave blank but note down the number after the patient data has been recorded in the online database. The number is displayed once (and only) after the patient data has been recorded in the online database.
- ⁴ Patient Age: If the patient is 2 years old or older, specify only the number of years, if between 1 and 23 months specify only the number of months, if less than 1 month specify the number of days.
- 5 If treatment based on biomarker, specify which one: **CRP** (C-reactive protein), **PCT** (Procalcitonin), **Other** lab-based biomarker other than CRP, PCT; or **WBC** (white blood cell count).
- ⁶ The unit for the biomarker CRP or PCT value expressed in mg/L, μg/L, ng/L, ng/dL, ng/dL, ng/mL, nmol/L. In thousand per microliter (μL) for WBC count (normal number of WBCs in the blood is 4,500 to 11,000 WBCs per microliter). For a conversion calculator see: http://unitslab.com/node/103 (procalcitonin).
- ⁷ Antimicrobial Name: Insert generic name.
- 8 Single Unit Dose: Numeric value for dose per administration (in grams, milligrams, IU or MU).
- ⁹ <u>Unit</u>: The unit for the dose (g, mg, IU or MU)
- Doses/day If necessary provide fractions of doses: (e.g., every 16h = 1.5 doses per day, every 36h = 0.67 doses per day, every 48h = 0.5 doses per day)
- 11 Route: Routes of administration are: Intravenous and intrathecal and intraperitoneal=P, Intramuscular=IM, Oral=O, Rectal=R, Inhalation=I. See also protocol page 18
- ¹² See <u>diagnoses</u> groups list (Appendix II)
- ¹³ See <u>Indication</u> codes (Appendix III)
- Reason in Notes: A diagnosis / indication for treatment is recorded in the patient's documentation (treatment chart, notes, etc.) at the start of antibiotic course (Yes or No)
- ¹⁵ <u>Guideline Compliance</u>: Refers to antibiotic choice (not route, dose, duration etc) in compliance with **local** guidelines (Y: Yes; N: No; NA: Not Assessable because of absence of local guidelines for the specific indication; NI: No Information because diagnosis/indication is unknown)
- ¹⁶ N missed doses: Number of missed doses from start date of current antibiotic treatment until the date of the survey. If no doses missed, report as 0. If unknown, leave field empty.
- ¹⁷ Reason: Reason for missed doses: due to **stock** out (S), patient could not **purchase** (P), **other** reason (O), **multiple** reasons (M), **unknown** (U).
- Treatment: Report "E" 1) when the antibiotic is being used as per a local guideline, treatment by which experience has proved to be beneficial; 2) when a culture or microbiological examination is not done; 3) when a microbiological examination is done, BUT not yet available on the day of the PPS; or the result was not assessable. Report "T" if based upon microbiological result; Report also "T" if the micro-organism yielded susceptible results.
- ¹⁹ Methicillin-resistant *Staphylococcus aureus* (MRSA)
- ²⁰ Methicillin-resistant coagulase negative staphylococci (MRCoNS)
- ²¹ Penicillin-non susceptible *Streptococcus pneumoniae* (PNSP)
- ²² Macrolide-lincosamide-streptogramin resistance in Streptococcus isolates (MLS)
- ²³ Vancomycin-resistant enterococci (VRE)
- ²⁴ Bacteria, producing extended-spectrum beta-lactamases (ESBL)
- ²⁵ Carbapenem-resistant *Enterobacterales* (CRE) enteric bacteria resistant to imipenem, meropenem or other carbapenems
- ²⁶ ESBL Non fermenters (ESBL-NF): *Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia spp., Stenotrophomonas maltophilia* multidrug resistant
- ²⁷ Carbapenem-resistant Nonfermenters (CR-NF) nonfermenters resistant to imipenem, meropenem or other carbapenems
- ²⁸ Multi-drug resistant (MDR) pathogens, others than the listed above
- ²⁹ Azoles: if the medicinal product chosen is intended to treat infections caused by azole-resistant fungi and yeasts (e.g. *Candida spp., Aspergillus spp.*)

GLOBAL-PPS PATIENT Form – additional variables for HAI at patient level (optional)

(Fill in one form per patient with an ongoing antimicrobial at 8am on the day of the PPS – more info on definitions in protocol, page 20)

| | A 1 | | | | | | | Patient Age 4 | Current Neonates (optional) | | | | _ | | |
|--|---|--|--------------------|---------|------------|-----------------|----------------------------|---|-----------------------------|-------|-----------|--------|-------------------------|------------------------|-----------------------|
| Ward Name/code | Activity ¹ (M, S, IC) | Patient Identi | ifier ² | S | urvey Numb | er ³ | Years | Months | Days | We | ight* | Gest | tatio- | Birth | Sex M, F, U |
| | (101, 3, 10) | | | | | | ≥ 2 years | 1-23 month | <1 month | | | nal | age* | weight* | IVI, F, U |
| | | | | | | | | | | | | | | | |
| Date of admission in t | • | | | | | | _ | al procedure du | ring current | admi | ssion in | 1 | ☐ Yes | □ No | UNK |
| (dd/mm/yyyy) (option | | | <u> </u> | | | | hospit | dl | | | | | | | |
| Previous hospitalization < 3 months (optional) | · Vos ICII Vos ethor No LINK Previous antihiotic course < | | | | | urse < 1 mor | nth <i>(o</i> | ptional | <i>'</i>) | ☐ Yes | ☐ No | | | | |
| , , , | | | I | | L | · L | | | | | | | | l | |
| "Inserted" invasive device | e present at 8 | am on the day | of the PP | S | | | | Date 1 st insertion (optional) | on/start | | McCal | | ☐ Non-1 | fatal diseas | se |
| Indwelling Urinary Cathet | er (UC) | | | | ☐ Yes | ☐ No | ☐ UNK | _//_ | | | score | 2 | Ultim | ately fatal | disease |
| Peripheral Vascular / intra | venous Cathe | eter (PVC) | | | ☐ Yes | □ No | ☐ UNK | _/_/_ | | | | | Rapid | lly fatal dis | ease |
| Central Vascular Catheter | , no implantal | ble venous port (| (CVC) | | ☐ Yes | □ No | ☐ UNK | _/_/_ | | | | | ☐ UNK/ | 'Not availa | ble |
| Non-invasive pos. & neg. ı | mechanical ve | entilation (CPAP, | BiPAP, CI | NEP,) | ☐ Yes | ☐ No | ☐ UNK | _/_/_ | | | | • | | | |
| Invasive respiratory endot | racheal intub | ation (IRI) ⁱ | | | ☐ Yes | □ No | ☐ UNK | _/_/_ | | | | | | | |
| Inserted tubes and drains | (T/D) ⁱⁱ | | | | ☐ Yes | □ No | ☐ UNK | _/_/_ | | | | | | | |
| | | | | | | | | | | | | | | | |
| Underlying morbidity | Diabete | s mellitus, type | 1 or 2 | | | Geneti | c disorder | | | End- | stage Liv | er Dis | sease, ciri | rhosis | |
| (multiple choice, | ☐ AIDS/HI | V (only if last CD | 4 count < | <500/mn | n³) | ☐ Conge | nital heart dis | eases | | Trau | ma | | | | |
| maximum 3 choices) | | ological or solid on the contract of the contr | - | ecent | | | - | es including cystic chiectasis, asthma | | | | _ | al diseas Coeliac di | e (inflamn isease,) | natory |
| | ☐ Stem ce | ell or solid organ | transplar | nt | | ☐ Neutro | penia | | | Chro | nic neur | ologic | cal condit | ions ⁱⁱⁱ | |
| |] | Renal Disease (a | | | | _ | ose steroids ^{iv} | | | Othe | | | | | |
| | | uberculosis | <u> </u> | | | ☐ Malnu | | | П | None | | | | | |
| | | | | | | Long C | | | | Unkr | | | | | |

ⁱ Include tracheostomy

ii Inserted tubes and drains: include nephrostomy tubes, intra-abdominal tubes and drains and cerebrospinal fluid shunts.

iii Chronic neurological conditions: include Alzheimer's disease, Parkinson's disease, dystonia, ALS (Lou Gehrig's disease), Huntington's disease, neuromuscular disease, multiple sclerosis and epilepsy etc.

iv Corticotherapy ≥ 30 days or recent corticotherapy at high doses (> 5 mg/kg prednisolone > 5 days)

Malnutrition refers to dietary deficiency which lead to lack of vitamins, minerals and other essential substances. Score illnesses as kwashiorkor, scurvy, delayed growth, serious underweight, etc.

HOSPITAL PROFILE - "Optional data" to be collected at hospital level

Provide, if available, for each indicator the year of reference and the number "at hospital level".

| , , | | |
|--|-------------|--------|
| | Year (yyyy) | Number |
| Hospital size : number (N) beds | | |
| Number of admissions (or discharges)/year | | |
| Number of patient days/year | | |
| Number of consumption of alcohol-based hand rub in litres/year | | |
| Number of "patients" with blood culture test/year | | |
| Number of stool tests for Clostridioides Difficile Infections/year | | |
| Number of FTE* antimicrobial stewardship physicians | | |
| Number of FTE antimicrobial stewardship pharmacists | | |
| Number of FTE Infection prevention control (IPC) doctors | | |
| Number of FTE Infection prevention control (IPC) nurses | | |
| were a light and in the control of t | | 1.1.1 |

Indicate for each indicator at hospital level if available 'yes' or 'no'

| | Yes | If yes: Year of introduction | No |
|--|-----|------------------------------|----|
| Presence of formally defined AMS* program | | | |
| Presence of active AMS group (committee and operational team) | | | |
| Presence of formally defined IPC* program | | | |
| Presence of active IPC group (committee and operational team) | | | |
| Presence of regular IPC (annual, quarterly) feedback to health care workers | | | |
| Clinical Infectious Disease (ID) consultation available | | | |
| Specialized AMS or ID training available for physicians/pharmacists | | | |
| Presence of microbiology lab support on site | | | |
| Availability of microbiology lab on weekends/holidays | | | |
| Availability of periodic cumulative antimicrobial susceptibility report** | | | |
| If yes, is susceptibility report distributed to prescribers? | | | |
| Availability of standardized criteria for appropriate IV-PO switch | | | |
| Software available for Infection Control and/or AMS | | | |
| Presence of bundles or checklists to decrease CAUTI, VAP, CR-BSI, CDIF, SSI° | | | |

^{*}AMS=Antimicrobial Stewardship; IPC=Infection Prevention and Control; ** local epidemiological report

Tick for each indicator if available at hospital level.

| | _ | - | | | |
|--|---|----------------|---------------------|-------------|-------|
| Availability of written policy to document the antimicrobial prescription in the medical record | | Yes, all wards | Yes, selected wards | Yes, in ICU | No |
| Availability of formal restriction procedure (defined formulary, restrictive list) for certain antimicrobials | | Yes, all wards | Yes, selected wards | Yes, in ICU | No |
| Presence formal review of antimicrobial after 48 hours (post-prescription review) | | Yes, all wards | Yes, selected wards | Yes, in ICU | No |
| Presence of antimicrobial ward rounds (Review of antimicrobial orders for assigned patients) | | Yes, all wards | Yes, selected wards | Yes, in ICU | No |
| Who can prescribe antibiotics in your hospital? | | Physician | Pharmacist | Nurse | Other |

^{*}FTE=Full-Time Equivalent units or equivalent employees working full-time on antimicrobial stewardship activities or IPC. E.g. if 3 employees work 20 hours, 30 hours and 10 hours/week=total 60 hours/week and assuming that a full-time employee works 40hours/week, the FTE calculation equals 60hours/40hours; or 1.5 FTE

[°] CAUTI=Catheter Associated Urinary Tract Infection; VAP=Ventilator Associated Pneumonia; CR-BSI=Catheter-related Blood Stream Infection; CDIF= Clostridioides Difficile Infection; SSI=Surgical Site Infections.

Appendix I: Combination anti-infective agents

Combinations of an antibiotic and a beta-lactamase inhibitor:

Ampicillin and beta-lactamase inhibitor: report only ampicillin dose (J01CR01) Amoxicillin and beta-lactamase inhibitor: report only amoxicillin dose (J01CR02) Ticarcillin and beta-lactamase inhibitor: report only ticarcillin dose (J01CR03) Piperacillin and beta-lactamase inhibitor: report only piperacillin dose (J01CR05) Imipenem and beta-lactamase inhibitor: report only imipenem dose (J01DH51) Panipenem and betamipron: report only panipenem (J01DH55)

Example:

Amoxicillin and beta-lactamase inhibitor 1.2g IV \rightarrow 1g (amoxicillin) + 200mg (clavulanic acid), **report** only 1 g as a dose

Piperacillin and beta-lactamase inhibitor 4.5g IV \rightarrow 4g (piperacillin) + 500mg (tazobactam), **report** only 4 g as a dose

Other combinations of multiple antimicrobial substances:

J01EE01 Sulfamethoxazole and Trimethoprim: **report the total amount of sulfamethoxazole and trimethoprim**

Example:

Co-trimoxazole 960mg: (sulfamethoxazole. 800mg + trimethoprim 160mg), report 960mg

Further information on agents included for the Global-PPS is available in the antimicrobial list. Only antimicrobial substance name needs to be written down, NOT the ATC codes! (excel file - available on website under documents: Global-PPS_antimicrobial_list.xlsx) http://www.global-pps.com/

Appendix II - Diagnostic codes (what the clinician aims at treating)

| Examples Prophylaxis for CNS (neurosurgery, meningococcal) Infections of the Central Nervous System Prophylaxis for Eye operations Therapy for Eye infections e.g., Endophthalmitis |
|---|
| Infections of the Central Nervous System Prophylaxis for Eye operations |
| Prophylaxis for Eye operations |
| |
| Liberany for Eye intections a di Endonbthalmitis |
| |
| Prophylaxis for Ear, Nose, Throat (Surgical or Medical prophylaxis=SP/MP) |
| Therapy for Ear, Nose, Throat infections including mouth, sinuses, larynx |
| Acute otitis media |
| |
| Lung abscess including aspergilloma |
| Upper Respiratory Tract viral Infections including influenza but not ENT |
| Acute Bron chitis or exacerbations of chronic bronchitis |
| Pneumonia or LRTI (lower respiratory tract infections) |
| Coronavirus disease caused by SARS-CoV-2 infection |
| Pulmonary TB (Tuberculosis) |
| Cystic fibrosis |
| Cardiac or Vascular Surgery, endocarditis prophylaxis |
| CardioVascular System infections: endocarditis, endovascular device e.g pacemaker, vascular graft |
| Gastro-Intestinal tract surgery, liver/biliary tree, GI prophylaxis in neutropenic patients or hepatic failure |
| Gastro-Intestinal infections (salmonellosis, Campylobacter, parasitic, etc.) |
| Intra-Abdominal sepsis including hepatobiliary, intra-abdominal abscess etc. |
| Clostridioides difficile infection |
| Prophylaxis for SST, for plastic or orthopaedic surgery (Bone or Joint) |
| Skin and Soft Tissue: Cellulitis, wound including surgical site infection, deep soft tissue not involving |
| bone e.g., infected pressure or diabetic ulcer, abscess |
| Bone/Joint Infections: Septic arthritis (including prosthetic joint), osteomyelitis |
| Prophylaxis for urological surgery (SP) or recurrent Urinary Tract Infection (MP) |
| Lower Urinary Tract Infection (UTI): cystitis |
| Upper UTI including catheter related urinary tract infection, pyelonephritis |
| Asymptomatic bacteriuria |
| Y Prophylaxis for OB stetric or GY naecological surgery (SP: section caesarean, no episiotomy; MP: |
| carriage of group B streptococcus) |
| Obstetric/Gynaecological infections, Sexually Transmitted Diseases (STD) in women |
| Genito-Urinary Males + Prostatitis, epididymo-orchitis, STD in men |
| Bacteraemia or fungaemia with no clear anatomic site and no shock |
| Sepsis of any origin (eg urosepsis, pulmonary sepsis etc), sepsis syndrome or septic shock with no |
| clear anatomic site. Include fungaemia (candidemia) with septic symptoms |
| |
| Human immunodeficiency virus |
| Pyrexia of Unknown Origin - Fever syndrome with no identified source or site of infection |
| Fever syndrome in the non-neutropenic Haemato-Onco patient with no identified source of pathogen |
| Fever in the N eutropenic patient |
| Lymphatics as the primary source of infection eg suppurative lymphadenitis |
| Disseminated infection (viral infections such as measles, CMV) |
| Antimicrobial prescribed with documentation but no defined diagnosis group |
| Drug is used as M edical P rophylaxis in gen eral, without targeting a specific site, e.g. antifungal |
| prophylaxis during immunosuppression |
| Completely Unk nown Indication |
| Antimicrobial (e.g. erythromycin) prescribed for Prok inetic use |
| Medical Prophylaxis for Maternal risk factors e.g. maternal prolonged rupture membranes |
| Drug is used as M edical P rophylaxis for Newborn risk factors e.g. VLBW (Very Low Birth Weight) and IUGR (Intrauterine Growth Restriction) |
| Chronic lung disease: long-term respiratory problems in premature babies (bronchopulmonary dysplasia) |
| 3 |

APPENDIX III - Type of Indication

| CAI Communit acquired infection | | Symptoms started ≤ 48 hours from admission to hospital (or present on admission). | | | | | | | |
|---|---|---|--|----------------------------|--|--|--|--|--|
| <u>HAI</u> | | HAI1 Post-operative surgice 90 days after implant surge | HAI1 Post-operative surgical site infection (within: 30 days of surgery OR; 90 days after implant surgery) | | | | | | |
| Healthcare Associated | | | HAI2 Intervention related infections of mixed origin (mix of CVC-BSI, PVC-BSI, VAP, CAUTI; or related to tubes/drains) | | | | | | |
| Infection: Symptoms | Inter- vention | HAI2-CVC-BSI (Central Ve | enous Catheter -related Bl | ood Stream Infection) | | | | | |
| start 48 hours | related | HAI2-PVC-BSI (Peripheral | Vascular Catheter-relate | ed Blood Stream Infection) | | | | | |
| after | HAI | HAI2-VAP (Ventilator Asso | ociated Pneumonia) | | | | | | |
| admission to hospital | | HAI2- CAUTI (Catheter As | sociated Urinary Tract In | fection) | | | | | |
| | | HAI3 C. difficile associated days after discharge from p | | | | | | | |
| | | HAI4 Other hospital acquire BSI) | HAI4 Other hospital acquired infection of mixed or undefined origin (HAP, UTI, | | | | | | |
| | | HAI4-BSI Blood Stream Infection, not intervention related | | | | | | | |
| | | HAI4-HAP Non-intervention related Hospital Acquired Pneumonia (not VAP) | | | | | | | |
| | | HAI4-UTI Urinary Tract Infection, not intervention related | | | | | | | |
| | | <u>HAI5</u> Patient readmitted <48h after stay in another hospital, with infection present on current admission or within 48 hours (patient with infection from another hospital) | | | | | | | |
| | | <u>HAI6</u> Infection present on admission from long-term care facility (LTCF) or Nursing Home* | | | | | | | |
| <u>SP</u> Surgical prophylaxis** | | SP1 Single dose | SP2 one day | <u>SP3</u> >1 day | | | | | |
| 24 hours in ord | For surgical patients , administration of prophylactic antimicrobials should be checked in the previous 24 hours in order to encode the duration of prophylaxis as either one dose, one day (= multiple doses given within 24 hours) or >1 day. | | | | | | | | |
| See more explanation and table in protocol page 8 ! | | | | | | | | | |
| MP Medical prophylaxis | | | | | | | | | |
| OTH Other | | For example erythromycin as a | a motility agent (motilin ag | gonist). | | | | | |
| <u>UNK</u> | (| Completely unknown indication | า | | | | | | |

Select 1 possibility for each reported antimicrobial

^{*}Long-term care facilities represent a heterogeneous group of healthcare facilities, with care ranging from social to medical care. These are places of collective living where care and accommodation is provided as a package by a public-agency, non-profit or private company (e.g. nursing homes, residential homes). **Surgical prophylaxis includes those antibiotics prescribed before and after a surgical intervention (surgery in the operation room). The code SP1, SP2, SP3 goes with a diagnostic code preceded by 'proph' (e.g. 'proph GI')

APPENDIX IV – list of micro-organisms by resistance type

| Microorganisms (MO) | Code | Resistance type - 1 | Resistance type - 2 | Resistance type - 3 |
|--|--------|---------------------|---------------------|---------------------|
| Staphylococcus aureus | STAAUR | MRSA | | |
| Staphylococcus epidermidis | STAEPI | MRCoNS | | |
| Staphylococcus haemolyticus | STAHAE | MRCoNS | | |
| Other coagulase-negative staphylococci (CNS) | STAOTH | MRCoNS | | |
| Streptococcus pneumoniae | STRPNE | PNSP | MLS | |
| Streptococcus spp., other or not specified | STROTH | MLS | | |
| Enterococcus faecalis | ENCFAE | VRE | | |
| Enterococcus faecium | ENCFAI | VRE | | |
| Enterococcus spp., other or not specified | ENCOTH | VRE | | |
| Neisseria meningitidis | NEIMEN | Other MDRO | | |
| Neisseria gonorrhoeae | NEIGON | Other MDRO | | |
| Listeria monocytogenes | LISMON | Other MDRO | | |
| Citrobacter freundii | CITFRE | ESBL | 3GCREB | CRE |
| Citrobacter spp., other or not specified | СІТОТН | ESBL | 3GCREB | CRE |
| Enterobacter cloacae | ENBCLO | ESBL | 3GCREB | CRE |
| Enterobacter spp. , other or not specified | ENBOTH | ESBL | 3GCREB | CRE |
| Escherichia coli | ESCCOL | ESBL | 3GCREB | CRE |
| Klebsiella aerogenes | KLEPAE | ESBL | 3GCREB | CRE |
| Klebsiella pneumoniae | KLEPNE | ESBL | 3GCREB | CRE |
| Klebsiella oxytoca | KLEOXY | ESBL | 3GCREB | CRE |
| Klebsiella spp., other or not specified | KLEOTH | ESBL | 3GCREB | CRE |
| Proteus mirabilis | PRTMIR | ESBL | 3GCREB | CRE |
| Proteus vulgaris | PRTVUL | ESBL | 3GCREB | CRE |
| Proteus spp., other or not specified | PRTOTH | ESBL | | CRE |
| Serratia marcescens | SERMAR | ESBL | 3GCREB | CRE |
| | SEROTH | ESBL | 3GCREB | CRE |
| Serratia spp., other or not specified | | ESBL | 3GCREB | |
| Morganella spp. | MOGSPP | ESBL | 3GCREB | CRE CRE |
| Providencia spp. | PRVSPP | | 3GCREB | CKE |
| Salmonella enteritidis | SALENT | ESBL | 3GCREB | |
| Salmonella typhi or paratyphi | SALTYP | ESBL | 3GCREB | |
| Salmonella typhimurium | SALTYM | ESBL | 3GCREB | |
| Salmonella spp., other or not specified | SALOTH | ESBL | 3GCREB | |
| Shigella spp. | SHISPP | ESBL | 3GCREB | |
| Yersinia spp. | YERSPP | ESBL | 3GCREB | |
| Other Enterobacterales | ETBOTH | ESBL | 3GCREB | CRE |
| Acinetobacter baumannii | ACIBAU | ESBL-NF | CR-NF | |
| Acinetobacter spp., other or not specified | ACIOTH | ESBL-NF | CR-NF | |
| Pseudomonas aeruginosa | PSEAER | ESBL-NF | CR-NF | |
| Stenotrophomonas maltophilia | STEMAL | CR-NF | | |
| Burkholderia cepacia | BURCEP | CR-NF | | |
| Burkholderia pseudomallei | BURPSE | CR-NF | | |
| Burkholderia mallei | BURMAL | CR-NF | | |
| ${\it Pseudomonadaceae family}\ , other\ or\ not\ specified$ | PSEOTH | ESBL-NF | CR-NF | |
| Campylobacter spp. | CAMSPP | Other MDRO | | |
| Helicobacter pylori | HELPYL | Other MDRO | | |
| Clostridioides difficile | CLODIF | Other MDRO | | |
| Clostridium spp., other or not specified | CLOOTH | Other MDRO | | |
| Other bacteria Mycobacterium, atypical | MYCATY | Other MDRO | | |
| Mycobacterium tuberculosis complex | MYCTUB | Other MDRO | | |
| Other bacteria | OTHER | Other MDRO | | |
| Candida spp. | CANSPP | Azoles | | |
| Aspergillus spp. | ASPSPP | Azoles | | |
| Other fungi | FUNG_ | Azoles | | |